Risk factors for diethylstilbestrol-associated clear cell adenocarcinoma

Obstetrics and Gynecology

Volumn 95, Issue 6, 2000, Pages 814-820

  Palmer, Julie R ^a,b,c   Anderson, Diane ^a,b,c   Helmrich, Susan P ^a,b,c   Herbst, Arthur L ^a,b,c  

^a BOSTON UNIVERSITY   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c DES Cancer Network   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIETHYLSTILBESTROL; ESTROGEN; ORAL CONTRACEPTIVE AGENT;

ADENOCARCINOMA; ARTICLE; CASE CONTROL STUDY; DRINKING BEHAVIOR; EPIDEMIOLOGY; FEMALE; HUMAN; PREGNANCY; PRENATAL EXPOSURE; RISK FACTOR; VAGINA TUMOR;

ADENOCARCINOMA, CLEAR CELL; ALCOHOL DRINKING; CASE-CONTROL STUDIES; CAUSALITY; CONTRACEPTIVES, ORAL; DIETHYLSTILBESTROL; ESTROGENS, NON-STEROIDAL; FEMALE; HUMANS; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RISK FACTORS; VAGINAL NEOPLASMS;

EID: 0034201977     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0029-7844(00)00827-9     Document Type: Article

References (14)

1. Smith OW, Smith GBS, Hurwitz D. Increased excretion of pregnanediol in pregnancy from diethylstilbestrol with special reference to the prevention of late pregnancy accidents. Am J Obstet Gynecol 1946;51:411-5.
2. Dieckmann W. Does the administration of diethylstilbestrol during pregnancy have therapeutic value? Am J Obstet Gynecol 1953;66:1062-81.
3. Herbst AL, Ulfelder H, Poskanzer DC. Adenocardnoma of the vagina: Association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med 1971;284:878-81.
4. Greenwald P, Barlow JJ, Nasca C, Burnett WS. Vaginal cancer after maternal treatment with synthetic estrogens. N Engl J Med 1971;285:390-2.
5. Noller KL, Decker DG, Lanier AP, Kurland LT. Clear cell adenocarcinoma of the cervix after maternal treatment with synthetic estrogens. Mayo Clin Proc 1972;47:620-30.
6. Melnick S, Cole P, Anderson D, Herbst A. Rates and risks of diethylstilbestrol related to clear cell adenocarcinoma of the vagina and cervix. N Engl J Med 1987;316:514-6.
7. Herbst AL, Anderson S, Hubby MM, Haenszel WM, Kaufman RH, Noller KL. Risk factors for the development of diethylstilbestrol-associated clear cell adenocarcinoma: A case-control study. Am J Obstet Gynecol 1986;154:814-22.
8. Hatch EE, Palmer JR, Titus-Ernstoff L, Noller KL, Kaufman RH, Mittendorf R, et al. Cancer risk in women exposed to diethylstilbestrol in utero. JAMA 1998;280:630-4.
9. Breslow NE, Day NE, Halvorsen KT, Prentice RL, Sabai C. Estimation of multiple relative risk functions in matched case-control studies. Am J Epidemiol 1978;108:299-307.
10. Tsutsui T, Suzuki N, Maizumi H, McLachlan JA, Barrett JC. Alteration in diethylstilbestrol-induced mutagenicity and cell transformation by exogenous metabolic activation. Carcinogenesis 1986;9:1415-8.
11. Herbst AL, Cole P, Norusis MJ, Welch WR, Scully RE. Epidemiologic aspects and factors related to survival in 384 registry cases of clear cell adenocarcinoma of the vagina and cervix. Am J Obstet Gynecol 1979;135:876-86.
12. Ginsburg ES, Mello NK, Mendelson JH, Barbieri RL, Teoh SK, Rothman M, et al. Effects of alcohol ingestion on estrogens in postmenopausal women. JAMA 1996;276:1747-51.
13. Sharp GB, Cole P. Identification of risk factors for diethylstilbestrol-associated clear cell adenocarcinoma of the vagina: Similarities to endometrial cancer. Am J Epidemiol 1991;134:1316-24.
14. Mittendorf R, Herbst AL. Diethylstilbestrol: An update. Cancer Prev 1992; August:1-12.